SCHEMBL1787225

SCHEMBL1787225

Cc1cnc2c(O)cccc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 1.00
PSMD14 O00487 1/20 0.62
COPS5 Q92905 1/20 0.62
CCR1 P32246 2/20 0.61
CCR5 P51681 2/20 0.61
CCR8 P51685 2/20 0.61
PARP1 P09874 1/20 0.58
METAP2 P50579 2/20 0.52
MMP2 P08253 1/20 0.52
CHRM1 P11229 1/20 0.52
TSHR P16473 1/20 0.52
COMT P21964 1/20 0.52
ADRA1A P35348 1/20 0.52
METAP1 P53582 1/20 0.52
HDAC8 Q9BY41 1/20 0.52
CYP1A2 P05177 1/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
SLC40A1 Q9NP59 1/20 0.47
ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9333864 0.98 KDM4E (0.96) KDM4EPSMD14COPS5CCR1CCR5
SCHEMBL27824094 0.98 KDM4E (0.96) KDM4EPSMD14COPS5CCR1CCR5
SCHEMBL20176003 0.81 KDM4E (0.73) KDM4EPSMD14COPS5PARP1METAP2
Jineol SCHEMBL29696064 0.80 KDM4E (0.67) KDM4EMETAP2MMP2CHRM1TSHR
Jineol SCHEMBL4213727 0.80 KDM4E (0.67) KDM4EMETAP2MMP2CHRM1TSHR
SCHEMBL7376462 0.80 PSMD14 (0.67) KDM4EPSMD14COPS5CCR1CCR5
SCHEMBL301595 0.79 KDM4E (0.62) KDM4EPSMD14COPS5CCR1CCR5
SCHEMBL2850764 0.78 PSMD14 (0.65) KDM4EPSMD14COPS5CCR1CCR5
Jineol SCHEMBL28133873 0.78 KDM4E (0.65) KDM4EMETAP2MMP2CHRM1TSHR
SCHEMBL9645971 0.78 KDM4E (1.00) KDM4EPSMD14COPS5METAP2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117534809-A Antibacterial aqueous polyurethane resin and preparation method and application thereof 上海华峰新材料研发科技有限公司 2024-02-09 CN claimed
CN-116851037-A Preparation method and application of hydroxyquinoline coordinated catalyst and compound 上海元革新材料科技有限公司 2023-10-10 CN claimed
US-5614635-A Method for the preparation of pyridine-2,3-dicarboxylic acids AMERICAN CYANAMID COMPANY (US) 1997-03-25 US claimed
EP-0331899-B1 A method for the sequential oxidation of substituted-8-hydroxy-quinolines to produce substituted-pyridine-2,3-dicarboxylic acids AMERICAN CYANAMID CO (US) 1994-04-27 EP claimed
EP-0259687-B1 METHOD FOR THE PREPARATION OF PYRIDINE-2,3-DICARBOXYLIC ACIDS AMERICAN CYANAMID COMPANY (US) 1991-07-03 EP claimed
EP-0331899-A2 A method for the sequential oxidation of substituted-8-hydroxy-quinolines to produce substituted-pyridine-2,3-dicarboxylic acids AMERICAN CYANAMID COMPANY (US) 1989-09-13 EP claimed
US-4816588-A OXIDATION OF 8-SUBSTITUTED QUINOLINES AMERICAN CYANAMID COMPANY (US) 1989-03-28 US claimed
EP-0259687-A2 Method for the preparation of pyridine-2,3-dicarboxylic acids AMERICAN CYANAMID COMPANY (US) 1988-03-16 EP claimed
JP-6211794-A None JP disclosed
EP-4623914-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-10-01 EP disclosed
CN-120035438-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2025-05-23 CN disclosed
CN-119390735-A Hydroxyquinoline coordinated catalyst, preparation method, composite catalyst and application 上海元革新材料科技有限公司 2025-02-07 CN disclosed
US-20240246916-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2024-07-25 US disclosed
WO-2024109684-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE 江苏亚虹医药科技股份有限公司 2024-05-30 WO disclosed
EP-0247277-B1 PROCESS FOR THE PREPARATION OF 5-ALKYLQUINOLINIC ACIDS AND MEANS FOR CARRYING OUT THIS PROCESS RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) 1991-09-11 EP disclosed
EP-0259687-B1 METHOD FOR THE PREPARATION OF PYRIDINE-2,3-DICARBOXYLIC ACIDS AMERICAN CYANAMID COMPANY (US) 1991-07-03 EP disclosed
EP-0331899-A2 A method for the sequential oxidation of substituted-8-hydroxy-quinolines to produce substituted-pyridine-2,3-dicarboxylic acids AMERICAN CYANAMID COMPANY (US) 1989-09-13 EP disclosed
US-4816588-A OXIDATION OF 8-SUBSTITUTED QUINOLINES AMERICAN CYANAMID COMPANY (US) 1989-03-28 US disclosed
EP-0259687-A2 Method for the preparation of pyridine-2,3-dicarboxylic acids AMERICAN CYANAMID COMPANY (US) 1988-03-16 EP disclosed
EP-0247277-A2 Process for the preparation of 5-alkylquinolinic acids and means for carrying out this process RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) 1987-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240246916-A1 7-NITRO-8-HYDROXYQUINOLINE DERIVATIVES, PREPARATION METHOD THEREFORE AND MEDICAL USE THEREOF CYP3A7, UGT1A7, UGT2B7 KDM4E 2921/4885PSMD14 1363/4885COPS5 1366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.